Sizing Is The New Fault Line

Overview

The apparel industry has navigated plenty of advancements and disruptions — fast fashion, e-commerce, the COVID-19 pandemic-era athleisure boom. But GIP and GLP-1 medications (collectively, “GLP-1”) represent something categorically different: a biological shift in the American body, happening at scale, faster than the industry’s planning and size-curve systems were designed to accommodate.

For the first time in decades, the obesity rate in the U.S. has declined, dropping from a peak of 39.9% in 2022 to 37% in 2025. Typical weight loss of 10%-20% of body weight equates to one-to-five clothing sizes (Bernstein, 2026). The implication is not a minor recalibration of size curves. It is a structural reset of the demand landscape.